Compare GSK plc (GSK) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs SYSCO Corporation — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while SYSCO Corporation trades at $82.25 (market cap $38.60B). The key difference: GSK plc is far larger — about 2.6× SYSCO Corporation's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | SYY | |
|---|---|---|
Market Cap | $101.34B | $38.60B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $91.16 |
52-Week Low | $36.20 | $69.30 |
Enterprise Value | $121.95B | $52.08B |
Dividend Yield | 3.49% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
SYY trades at $82.32, down 0.64% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026. Revenue growth remains steady, reaching $81.37B in 2025, while net income margin is 2.08%. The company maintains positive cash flow and announced a $0.55 dividend for July 2026.
Outlook is positive with a consensus price target of $83.67, though risks include margin pressure and debt levels. The stock offers value with a P/S of 0.47, but investors should monitor Q2 2026 earnings and industry headwinds. Institutional sentiment is bullish, with 60% buy ratings among analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
